Varenicline in Drug Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of varenicline compared to placebo in tobacco dependent individuals who are undergoing concurrent treatment for alcohol dependence. As they will be inpatients and under 24 hour medical care for the first 21 days of treatment, or receiving outpatient treatment through the Alcohol Research and Treatment Clinic, this will allow for a comprehensive assessment of the safety of varenicline in this population with minimal risk of adverse consequences. The patients will continue their cessation treatment for an additional 10 weeks as outpatients through the Nicotine Dependence Clinic at CAMH. They will also be contacted at 6 months for follow-up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Varenicline For Smokers In Recovery From Alcohol Dependence

NCT01092702

Tobacco Abstinence

COMPLETED PHASE2/PHASE3

Do Treatments for Smoking Cessation Affect Alcohol Drinking?

NCT00580645

Alcohol Drinking

COMPLETED PHASE2

Varenicline Treatment for Active Alcoholic Smokers

NCT01347112

Smoking Tobacco Dependence Alcohol Dependence

COMPLETED PHASE2/PHASE3

Effects of Varenicline in Heavy Drinking Smokers

NCT02488889

Cigarette Smoking Alcohol Consumption

WITHDRAWN PHASE4

Varenicline and Alcohol in Inpatient Addictions Program (IAP)

NCT01169610

Alcoholism Nicotine Dependence

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Drinking alcohol and cigarette smoking are closely associated and use of one often leads to the use of the other. Also, since tobacco-related illness is the number one cause of death among recovered alcoholics it is imperative that we provide strong evidence-based treatment options for this population. Since smoking can be a strong trigger to drink in those who are dependent on both alcohol and tobacco, treating both at the same time may result in better treatment outcomes. This study will examine the efficacy of starting smoking cessation treatment while patients are in residential treatment for alcohol dependence, or outpatient in the Alcohol Research and Treatment Clinic. It will compare the effectiveness of varenicline, the most effective medication for smoking cessation with placebo. Both groups will receive weekly cessation counselling and support by a trained research analyst. We will measure abstinence from smoking at the end of the 12-week treatment period and again after 6-months to determine longer-term smoking cessation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Cessation Alcohol Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

varenicline group

Group Type ACTIVE_COMPARATOR

varenicline

Intervention Type DRUG

one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication

placebo group

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

varenicline

one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication

Intervention Type DRUG

placebo

lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Champix Chantix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* current daily smokers enrolled in residential treatment or outpatient in Alcohol Treatment and Research Clinic for Alcohol Use Disorder at CAMH
* smoke minimum of 10 cigarettes per day
* Fagerstrom Test of Nicotine Dependence score \> 3
* able to provide written informed consent
* able and willing to attend weekly appointments at the NDC following discharge

Exclusion Criteria

* any serious medical condition requiring immediate investigation or treatment
* pregnancy or lactation
* current DSM-IV Axis I psychiatric disorder
* any know contraindication to using varenicline

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No